Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides

Taste Disorder, Secondary, Sweet Clinical Trial

Official title:

The Role of Sweet Taste Receptor Blockade on Intragastric Liquid Meal-stimulated Secretion of Satiation Peptides in Healthy Humans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01302574
• Other study ID #: EKBB 69/04.02
• Status: Completed
• Phase: Phase 1
• First received: February 22, 2011
• Last updated: February 23, 2011
• Start date: January 2010
• Est. completion date: June 2010

Study information

• Verified date: February 2011
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of gastrointestinal (GI) satiation peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gastrointestinal tract.

Description:

There is strong evidence that taste signaling mechanisms identified in the oral epithelium also operate in the gut. It is suggested that open-type enteroendocrine cells directly sense nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon like peptide-1 (GLP-1) and peptide YY (PYY). Several nutrient responsive G-protein coupled receptors have been identified in the human gut, including the sweet taste responsive T1R2/T1R3 heterodimer, the amino acid/umami responsive T1R1/T1R3 as well as GPR120 for unsaturated long-chain free fatty acids. The functional significance of sweet taste receptors in mixed liquid meal-stimulated secretion of GLP-1 and PYY will be determined by intragastric infusion of a 500 mL mixed liquid meal with or without lactisole (450 ppm)in a double blind, 2-way crossover trial including 16 healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: June 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• healthy subjects

• BMI of 19.0-24.5

• age 18-40 years old

• stable body weight for at least 3 month

Exclusion Criteria:

• smoking

• substance abuse

• regular intake of medication

• medical or psychiatric illness

• gastrointestinal disorders or food allergies

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Taste Disorder, Secondary, Sweet
• Taste Disorders

Intervention

Dietary Supplement:
• lactisole
Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.

Locations

Country	Name	City	State
Switzerland	University Hospital Basel, Phase 1 Research Unit	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gastrointestinal peptide secretion		2 hours blood sampling	No
Secondary	Appetite perceptions		4 hours	No
Secondary	Gastric emptying rate		4 hours	No